
- Telehealth Visits
- Insurance plan information

Pamela N. Munster, MD
Medical Oncology • HematologyCo-director, Center for BRCA Research- Telehealth Visits
- Insurance plan information
Cancer Clinical Trials & Investigational Treatments Mission Bay



Pamela N. Munster, MD
Medical Oncology • HematologyCo-director, Center for BRCA ResearchCancer Clinical Trials & Investigational Treatments Mission Bay
- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Pamela N. Munster is a medical oncologist who cares for patients with breast cancer. Her roles include director of the early-phase clinical trials program for cancer research; co-director of the UCSF Center for BRCA Research; and co-leader of UCSF's program in developmental therapeutics, which focuses on innovative research to find treatments for advanced cancer.
In her own research endeavors, Munster is interested in developing new targeted therapies for treatment-resistant cancer. She studies changes in gene expression and resistance to therapy. Her lab is involved in projects evaluating hormone therapies for breast cancer as well as therapies that engage the immune system to fight tumors. She has published in numerous scientific journals and lectured on topics in breast oncology, such as the management of metastatic breast cancer, breast cancer receptors, clinical trials and translational research (the process of applying study findings to patient care). She has a published memoir, “Twisting Fate: My Journey with BRCA – From Breast Cancer Doctor to Patient and Back.”
Munster earned her medical degree from the University of Bern in Switzerland. She completed a residency in internal medicine at Indiana University Health, followed by a fellowship in medical hematology and oncology at Memorial Sloan Kettering Cancer Center, where she also served as faculty in the breast cancer program.
Prior to joining UCSF, Munster worked for six years in the Moffitt Cancer Center's division of breast oncology and experimental therapeutics program, serving as scientific director of breast research and co-chair of the phase 1 clinical trial program.
Education & training
Board certification
- Medical Oncology, American Board of Internal Med/Medical Oncology
Residency
- Internal Medicine, Indiana University Hospitals School of Med - GME
Internship
- Internal Medicine, Indiana University Hospitals School of Med - GME
Degree
- MD, University of Berne
My expertise
Specialties
Conditions
Locations
My research
Publications
Showing 1-6 of 19 reviews
Sort by
- February 18, 20265 out of 5 Stars
Love Dr Munster
- January 29, 20265 out of 5 Stars
Dr Munster was excellent
- January 21, 20265 out of 5 Stars
Pam Munster, MD is an extraordinary doctor and human being. I feel very lucky for the opportunity to work together.
- January 6, 20265 out of 5 Stars
Wonderful, highly competent and very caring
- December 19, 20255 out of 5 Stars
I can't say enough good things about Dr. Munster.
- October 15, 20255 out of 5 Stars
I am totally happy with Dr. Munster. She is smart, professional and caring. This is the first time that I feel like I am in good hands...I trust her with my care. I have recommended her to others and always share about my experiences when asked.
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.